Himmelstein, Russell
Guth, Sarah
Enenbach, Michael
Gleason, Mary Margaret
Stevens, Hanna
Glowinski, Anne
Kolevzon, Alex
Martin, Andrés http://orcid.org/0000-0001-6425-5158
Funding for this research was provided by:
National Institute of Mental Health (R25 MH077823)
Child Study Center, Yale School of Medicine (Riva Ariella Ritvo Endowment)
Klingenstein Third Generation Foundation
Article History
Received: 3 November 2019
Accepted: 12 February 2020
First Online: 25 February 2020
Compliance with Ethical Standards
:
: This study was deemed exempt by the Yale Human Research Protection Program’s Human Investigations Committee (protocol #2000026782).
: Supported by the Klingenstein Third Generation Foundation, which had no role in the analysis or drafting of this report. Additional support provided by the Riva Ariella Ritvo Endowment at the Yale School of Medicine, and by NIMH R25 MH077823, ‘Research Education for Future Physician-Scientists in Child Psychiatry’.
: Dr. Glowinski reports funding support from the National Institute of Mental Health and is a member of the ACGME Psychiatry Residency Review Committee. Dr. Kolevzon receives research support from AMO Pharma and has consulted to Ovid Therapeutics, Takeda, 5 AM Ventures, LabCorp, sema4 and Coronis Neurosciences. He sits on the advisory board of the Phelan-McDermid Syndrome Foundation. Dr. Stevens reports funding support from the National Institutes of Health, the Nellie Ball Trust and the Roy J. Carver Trust. Drs. Glowinski, Kolevzon and Stevens sit on the advisory board of the Klingenstein Third Generation Foundation. The other authors have no conflicts to declare.